We have determined the pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of rocuronium in infants and children. We studied infants (n:5, 0.1-0.8 yr) and children (n:5, 2.3-8 yr), ASA II, in the ICU while undergoing artificial ventilation under i.v. anaesthesia with an arterial cannula in situ and the EMG of the adductor pollicis muscle was monitored. Rocuronium 0.06 (infants) and 0.09 (children) mg kg 91 min 91 was given i.v. over Ϯ5 min until 85% neuromuscular block was obtained. Arterial blood samples were obtained over 240 min. Plasma concentrations were measured by HPLC. Pharmacokineticdynamic variables were calculated using the Sheiner model and the Hill equation. Statistical analysis was performed using the Mann-Whitney U test (P:0.05). The mean administered dose was 0.32 (SD 0.08) mg kg Rocuronium is an intermediate-acting non-depolarizing neuromuscular blocking agent that has a faster onset of action than other non-depolarizing neuromuscular blocking agents.
Rocuronium is an intermediate-acting non-depolarizing neuromuscular blocking agent that has a faster onset of action than other non-depolarizing neuromuscular blocking agents. 1 There are only two studies comparing the neuromuscular effects of rocuronium in infants with those in children. 2 3 These investigators obtained different results in that Woelfel and colleagues found that a fixed dose of rocuronium 0.6 mg kg 91 had a longer neuromuscular blocking effect and a slower recovery in infants than in children. 2 4 Taivainen and colleagues administered individually determined ED 95 doses of rocuronium to infants, children and adults and found a similar duration of effect and recovery rate of neuromuscular function in all three age groups. 3 These apparently conflicting results may be explained by the pharmacokinetics of rocuronium. However, pharmacokinetic data currently available for rocuronium in infants are limited and cannot be used to explain the above pharmacodynamic differences. 5 We designed a study to analyse the pharmacokinetics and pharmacodynamic-kinetic relationship of rocuronium in infants and children in order to rationalize these apparently conflicting results in the literature and to contribute to the development of rational dose regimens.
Patients and methods
After obtaining institutional Ethics Committee approval and parental written informed consent, we studied five infants and five children, ASA II, in the intensive care unit during stable recovery from elective tracheal or cardiovascular surgery, that is in a state of haemodynamic stability without supportive medication, normal peripheral (932.5ЊC) and core (936.5ЊC) temperatures, and normal values for blood chemistry, plasma proteins and packed cell volume. All patients were studied in the same intensive care unit. This site was chosen to guarantee stable cardiovascular and respiratory status of the patients, in the absence of surgical manipulations or bleeding during the study period, to allow an arterial cannula for arterial sampling to obtain reliable plasma concentrations for modelling. Surgical procedures in the patients are listed in table 1. Patients receiving medications or with diseases known to affect neuromuscular function, or patients with signs of hepatic or renal dysfunction were excluded.
Patients were routinely sedated and their lungs ventilated with the aid of i.v. bolus doses of morphine and midazolam. Before calibration of the neuromuscular device patients received thiopentone 2-6 mg kg 91 and alfentanil 20-80 g kg 91 to guarantee a sufficient level of anaesthesia during the period of neuromuscular block. Standard monitoring included ECG, pulse oximetry, continuous core and palmar skin temperature monitoring, and invasive arterial pressure measurement.
NEUROMUSCULAR MONITORING AND SEQUENCE OF EVENTS
The arm opposite to the arm with the arterial cannula was used for neuromuscular measurements, that is adductor pollicis muscle electromyography (Relaxograph, Datex, Finland) after supramaximal train-of-four (TOF) stimulation (4 stimuli at a frequency of 2 Hz every 10 s). Surface stimulating electrodes were attached over the ulnar nerve on the wrist and recording electrodes over the adductor pollicis muscle, over the proximal volar surface of the index finger and at the radial side of the wrist distal to the stimulating electrodes. 6 Palmar skin temperature was obtained from the same hand. A stable calibration signal of the electromyographic trace was awaited before rocuronium was administered. Neuromuscular block was defined as percentage depression of the first EMG twitch response (T1) of the TOF compared with the baseline calibration response. After infusion of rocuronium, neuromuscular function was recorded in every patient until full spontaneous recovery of the EMG response had occurred. The stable twitch response after recovery (Tc) was used as a reference value to calculate EMG recovery data. The time of maximal neuromuscular block after rocuronium infusion and times from maximum block until recovery of T1 to 25% and 75% of Tc and to a train-of-four ratio (T4/T1) of 0.7 (DUR 0.7 ) were calculated. The recovery index (RI 25-75% , time of T1 recovery from 25% to 75% of Tc) was derived from these data.
Rocuronium was administered by a continuous infusion joined by a needle to a rubber attachment of a steadily running central venous cannula. In five infants rocuronium, diluted in physiological saline to a concentration of 0.1 mg ml
91
, was infused end to side to a running peripheral venous cannula at a rate of 0.06 mg kg 91 min 91 until a decrease in twitch height of 85% was obtained. The infusion was then stopped to prevent occurrence of complete block. In five children, rocuronium, diluted in physiological saline to a concentration of 0.3 mg ml
, was infused via a peripheral venous cannula at a rate of 0.09 mg kg 91 min 91 also until 85% block was obtained. Blood samples (0.5 ml) were obtained from an arterial cannula at the following times: one blank sample immediately before administration of rocuronium; five samples during onset of neuromuscular block at various degrees of block, that is at 1 and 2 min after the start of infusion and at approximately 20, 50, and 80% of block; one sample at maximum block; three samples at approximately 20%, 55% and 90% recovery of T1; and at 30, 45, 60, 90, 120, 180 and 240 min after disconnection of the infusion. Total sampling volume was restricted to less than 2% of the circulating blood volume of infants and to less than 1% of the circulating blood volume of children. Samples were stored in lithium heparinized tubes at room temperature until centrifugation, which took place within 4.5 h after the start of sampling. Plasma samples were stored at 920ЊC after centrifugation. After completion of the study all samples were transported on dry ice to the analytical laboratory and stored at 918ЊC until analysis.
SAMPLE ANALYSIS
Concentrations of rocuronium (Org 9426) and its putative derivatives, 17-desacetyl-rocuronium (Org 9943) and 16-N-desallyl-rocuronium (Org 20860), were analysed by HPLC as described previously. 7 Using this method precision was almost independent of concentration and was 8%, 7% and 12% for rocuronium (10-20 000 ng ml ), respectively. The accuracy for rocuronium, expressed as percentage recovered of the added amount, was 86%, 103%, 107% and 98% at concentrations of 10, 1000, 5000 and 10 000 ng ml
91
, respectively. At 20 and 200 ng ml
, accuracy was 92% and 106% for Org 9943, and 93% and 111% for Org 20860, respectively. The lower limit of quantification, defined as the lowest concentration that could be determined with a precision and accuracy greater than 15%, was 10, 20 and 20 ng ml 91 for rocuronium, Org 9943 and Org 20860, respectively.
PHARMACOKINETIC ANALYSIS
Pharmacokinetic analysis was based on iterative, non-linear, least-squares regression analysis by the computer program Multifit using the Marquardt minimizing algorithm. 8 Initial estimates were obtained by a stripping procedure. For each individual patient the parameters of a two-or threeexponential equation were fitted to the logarithm of the plasma concentration-time data pairs, assuming a constant relative error. The choice between a twoor three-compartment model was made on the F test, accepting a more complex model as significantly better fitting if P:0.05. Relevant pharmacokinetic variables were calculated using standard equations, assuming the elimination to take place from the central compartment. 9 
PHARMACOKINETIC-DYNAMIC MODELLING
The concentration-effect data were analysed using the computer program PkPdFit, the T1 data of the EMG and the values of the coefficients and exponents of a multiexponential equation, describing the concentration vs time data in plasma. For each individual patient the variables of the model of Sheiner and colleagues, 10 that is the rate constant between plasma and effect compartment (k eo ), the concentration in the effect compartment at 50% block (EC 50 ) and the sigmoidicity coefficient of the Hill equation (␥) were fitted to the effect using equal weight for each measurement. The fit was optimized with Simplex as the minimizing algorithm, 11 
Results

PHARMACODYNAMICS
Patient data are shown in table 1. Tracheal resections had been performed 7 and 11 days before the study while other procedures had been finished 3-20 h before the start of the modelling study. All open heart surgical procedures were performed under normothermic conditions with a mean duration of extracorporeal perfusion of 33 (13) min. Mean time between the end of extracorporeal perfusion and initiation of this study was 7.9 h. The interval between the last dose of intraoperative neuromuscular blocking agent and the start of the modelling study was always more than 10 times the elimination half-life of the blocker given during operation. None of the patients had infusions of vasoactive drugs. Core and palmar skin temperatures did not differ between the groups during the study and averaged 36.9 (0.3) ЊC and 34.6 (1.5) ЊC, respectively. Mean duration of calibration was 16 (8) min. In infants, 0.32 (0.08) mg kg 91 of rocuronium established 96.9 (2.9) % block in 6.6 (1.6) min. In children, these values were 0.4 (0.1) mg kg 91 , 96.5 (0.7)% and 5.9 (1.4) min, respectively (ns). RI 25-75% and DUR 0.7 were 9.1 (4.7) and 21.5 (11.8) min in infants, and 6.3 (0.7) and 14.0 (1.1) min in children, respectively (ns). Figure 1 Representative example of a three-compartmental fit of plasma concentration decay of rocuronium in an infant. 
Discussion
This study was carried out under conditions that may differ from those in the operating theatre and in postoperative cardiac surgery patients. Although this may create limitations, we believe that the data may well be valid for developing dose regimens for general anaesthetic practice for the following reasons. (1) Our time course results were in agreement with those of other investigators, obtained in comparable age groups. (2) Our simulations with the PK/PD data predicted findings obtained previously for infants and children (see below). (3) Our patients were in a stable cardiovascular state without supportive medication and had normal values for blood chemistry, plasma proteins and packed cell volume. (4) The study was not commenced before at least 10 half-lives of the neuromuscular blocking agent used during operation had elapsed.
PHARMACODYNAMICS
We found a similar time course of neuromuscular recovery after an ED 95 dose of rocuronium administered by infusion in infants and children. This result supports the study of Taivainen and colleagues. 3 Why, then, did Woelfel and colleagues find that after a constant dose of rocuronium 0.6 mg kg
91
, infants showed recovery times twice as long as those of children? 24 Our pharmacokinetic-pharmacodynamic data allowed us to model a pharmacokinetic-dynamic relationship in each individual patient for any dose of rocuronium. We simulated the time course of action of an individual ED 90 and of a fixed dose of 0.6 mg kg 91 in infants and children ( fig. 3) . Figure 3 demonstrates clearly how infants show a duration of effect of rocuronium twice as long as that of children after a constant dose of 0.6 mg kg 91 , despite similar time courses after an individual ED 90 . If a dose of 0.6 mg kg 91 is replaced by an intubating dose of twice the mean ED 90 values in infants and children, the difference becomes less pronounced but is still clinically relevant. Dur 25% of intubating doses (2 ED 90 , i.e. 0.52 mg kg 91 for infants and 0.67 mg kg 91 for children), calculated on the basis of the model, were 24 (8) and 14 (2) min and RI 25-75% 16 (7) and 8 (1) min for infants and children, respectively. Although our models in infants and children were based on data obtained in a limited number of patients under stable conditions in the postoperative period, their validity for prediction of the time course in these categories appears good because the outcome is supported in studies in which pharmacodynamic characteristics of different doses of rocuronium in paediatric patients have been evaluated. [2] [3] [4] 
PHARMACOKINETICS
We found several important pharmacokinetic differences between infants and children. Cl pl of rocuronium was significantly smaller while V ss was greater in infants than in children. This resulted in an MRT iv which was twice as long in infants as in children. These kinetic differences between infants and children resulted in protracted recovery of neuromuscular function in infants after a large bolus dose or repeated doses, as demonstrated by the modelling results shown in figure 3 .
O'Kelly and co-workers also found positive correlations of weight-normalized clearance with age and weight. 5 For children aged 1-8 yr with a body weight of 10-25 kg, their results were in good agreement with our findings, as illustrated in figure 4 .
Deviation of the results of our study in infants from those of O'Kelly and co-workers could reflect the method of data analysis used by O'Kelly and colleagues, who pooled data of children of various ages in their study. In contrast, Vuksanaj and Fisher reported that clearance (per kg body weight) in children aged 4-11 yr declined with age and body weight. 12 This apparent difference may be partly an artefact because of inclusion of extremely obese children, in particular in the age range 9-11 yr, resulting in an apparently small value for weightnormalized clearance. Over the range 5-8 yr, or 18-25 kg, which coincides with the age groups in the three studies, the differences between the studies are rather small (fig. 4) . It is likely that weight-normalized clearance is maximal for children of 5-8 yr, or 18-25 kg, and declines with increasing age and body weight. This decline is likely to be related to declining body surface area/body weight ratio. Assuming a value of 4.0 ml min 91 kg 91 for clearance of a normal adult, 13 clearance normalized for body surface area is 150 ml min 91 m 92 for both adults and children. Figure 4 demonstrates that for children less than about 3 yr, clearance is lower than predicted from values of older children and adults. This lower clearance may reflect immaturity of the liver and kidneys, the main eliminating organs. 14 We observed a negative correlation for weightnormalized volume of distribution at steady state and age and body weight. In contrast, O'Kelly and colleagues found that volume of distribution increased slightly with age and weight, 5 whereas Vuksanaj and Fisher did not find a significant trend in their study in children aged 4-11 yr. 12 One can only speculate on the reason for these differences. It is possible that the different methodologies in the three studies may have created the observed differences. Comparing our results with weight-normalized volume of distribution at steady state in adults (205 ml kg 91 ), 13 it may be concluded that in children aged 4-8 yr, V ss is lower than in adults. In contrast, V ss in infants is higher than in adults and children. The distribution of quaternary compounds such as rocuronium and other neuromuscular blocking agents is limited to the extracellular fluid (ECF). During the first year of life, the volume of ECF decreases from 44% of body weight at birth to about 22% of body weight at 1 year, a value close to that in adults. 15 The higher percentage ECF predicts a higher V ss in infants compared with children and adults.
The larger plasma clearance and lower volume of distribution in children compared with both infants and adults resulted in a markedly lower mean residence time and a shorter duration of neuromuscular block. A short duration of action of an intubating dose of rocuronium has been observed in children compared with infants 2 16 and adults. 17 Other non-depolarizing neuromuscular blocking agents do not seem to show similar correlations between pharmacokinetic variables and patient characteristics in children. All existing studies support the concept that the volume of distribution of a neuromuscular blocking agent is larger in infants than in children, [18] [19] [20] [21] [22] in accordance with the larger percentage of extracellular fluid. For plasma clearance the situation is different. Studies with atracurium revealed that plasma clearance is larger in infants than in children. 21 22 This may be explained by the organ-independent elimination rate in combination with the larger volume of distribution. A study with vecuronium showed similar plasma clearance in both age groups, 20 and studies with d-tubocurarine indicated that plasma clearance may be smaller in infants compared with children. 18 19 The latter finding may result from the relatively large contribution of renal clearance in elimination, compared with vecuronium. 
PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIP
Our results showed that infants needed a lower concentration of rocuronium in the effect compartment than children in order to produce the same degree of neuromuscular block. This result corroborates data available for d-tubocurarine and vecuronium. [18] [19] [20] The lower effective concentrations in infants may be because of their potentially lower quantal content of acetylcholine, as shown in newborn rats, the larger incidence of single molecule block in infancy, and/or less protein binding as a result of low concentrations of plasma proteins in infants. 14 23 24 The slope of the concentration-response relationship based on the Hill equation was steeper in infants than in children. This finding supports the previous study of dose-response curves of rocuronium in infants, children and adults which showed the steepest slope in infants. 3 This steeper slope in infancy may be a unique characteristic of rocuronium as this phenomenon has not been seen with other neurornuscular blocking agents. 18 20 22 
